Literature DB >> 12393730

CCR7-mediated physiological lymphocyte homing involves activation of a tyrosine kinase pathway.

Jens V Stein1, Silvia F Soriano, Christine M'rini, César Nombela-Arrieta, Gonzalo González de Buitrago, José Miguel Rodríguez-Frade, Mario Mellado, Jean-Philippe Girard, Carlos Martínez-A.   

Abstract

Homing of blood-borne lymphocytes to peripheral lymph nodes (PLNs) is a multistep process dependent on the sequential engagement of L-selectin, which mediates lymphocyte rolling along the luminal surface of high endothelial venules (HEVs), followed by activation of lymphocyte integrins and transmigration through HEVs. Within lymphoid tissue, B and T lymphocytes then migrate toward specific microenvironments such as B-cell follicles and the paracortex, respectively. The lymphocyte-expressed chemokine receptor CCR7 is playing an important role during this process, as its HEV-presented ligands CCL19 and CCL21 can trigger rapid integrin activation under flow in addition to inducing a chemotactic response, which may participate in transmigration and/or interstitial migration. Here, we report that Tyrphostin (Tyr) AG490, a pharmacological inhibitor of Janus family tyrosine kinases (Jaks), blocked the chemotactic response of primary mouse lymphocytes to CCL19 and CCL21 in a dose-dependent manner. Furthermore, Tyr AG490 inhibited rapid CCL21-mediated up-regulation of alpha4 and beta2 integrin adhesiveness in static adhesion assays and under physiological flow, whereas adhesion induced by phorbol myristate acetate remained unaltered. Using intravital microscopy of subiliac PLNs in mice, we found that adoptively transferred Tyr AG490-treated lymphocytes adhered significantly less in HEVs compared with control cells, although L-selectin-mediated rolling was similar in both samples. Finally, we observed rapid Jak2 phosphorylation in CCL21-stimulated primary mouse lymphocytes. Thus, our study suggests a role for Jak tyrosine kinases during CCR7-mediated lymphocyte recirculation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393730     DOI: 10.1182/blood-2002-03-0841

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  Comparison of immortalized bEnd5 and primary mouse brain microvascular endothelial cells as in vitro blood-brain barrier models for the study of T cell extravasation.

Authors:  Oliver Steiner; Caroline Coisne; Britta Engelhardt; Ruth Lyck
Journal:  J Cereb Blood Flow Metab       Date:  2010-07-07       Impact factor: 6.200

Review 2.  Targeted Therapy in Chronic Lymphocytic Leukemia.

Authors:  Thomas J Kipps; Michael Y Choi
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

Review 3.  Chronic Pancreatitis and the Development of Pancreatic Cancer.

Authors:  Hemanth K Kandikattu; Sathisha U Venkateshaiah; Anil Mishra
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2020       Impact factor: 2.895

4.  Vav1 and Rac control chemokine-promoted T lymphocyte adhesion mediated by the integrin alpha4beta1.

Authors:  David García-Bernal; Natalia Wright; Elena Sotillo-Mallo; César Nombela-Arrieta; Jens V Stein; Xosé R Bustelo; Joaquin Teixidó
Journal:  Mol Biol Cell       Date:  2005-05-04       Impact factor: 4.138

5.  CXCL12-mediated murine neural progenitor cell movement requires PI3Kβ activation.

Authors:  Borja L Holgado; Laura Martínez-Muñoz; Juan Antonio Sánchez-Alcañiz; Pilar Lucas; Vicente Pérez-García; Gema Pérez; José Miguel Rodríguez-Frade; Marta Nieto; Oscar Marín; Yolanda R Carrasco; Ana C Carrera; Manuel Alvarez-Dolado; Mario Mellado
Journal:  Mol Neurobiol       Date:  2013-04-19       Impact factor: 5.590

6.  Leukocyte RhoA exchange factor Arhgef1 mediates vascular inflammation and atherosclerosis.

Authors:  Maria Luigia Carbone; Gilliane Chadeuf; Sandrine Heurtebise-Chrétien; Xavier Prieur; Thibault Quillard; Yann Goueffic; Nathalie Vaillant; Marc Rio; Laure Castan; Maxim Durand; Céline Baron-Menguy; Julien Aureille; Juliette Desfrançois; Angela Tesse; Raul M Torres; Gervaise Loirand
Journal:  J Clin Invest       Date:  2017-11-13       Impact factor: 14.808

7.  The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK.

Authors:  J Rudolph; A Heine; T Quast; W Kolanus; J Trebicka; P Brossart; D Wolf
Journal:  Leukemia       Date:  2016-05-25       Impact factor: 11.528

Review 8.  Molecular mechanisms deployed by virally encoded G protein-coupled receptors in human diseases.

Authors:  Silvia Montaner; Irina Kufareva; Ruben Abagyan; J Silvio Gutkind
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012-10-22       Impact factor: 13.820

9.  Impaired chemokine-induced migration during T-cell development in the absence of Jak 3.

Authors:  Gloria Soldevila; Ileana Licona; Alfonso Salgado; Marcela Ramírez; Ramsés Chávez; Eduardo García-Zepeda
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

10.  Jak3 is involved in dendritic cell maturation and CCR7-dependent migration.

Authors:  Ana Rivas-Caicedo; Gloria Soldevila; Teresa I Fortoul; Andrés Castell-Rodríguez; Leopoldo Flores-Romo; Eduardo A García-Zepeda
Journal:  PLoS One       Date:  2009-09-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.